Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Multiple Myeloma—Better Drugs Ask for More Stringent Evaluations

Multiple Myeloma—Better Drugs Ask for More Stringent Evaluations Research Original Investigation Carfilzomib, Lenalidomide, and Dexamethasone With Lenalidomide International Myeloma Workshop Consensus Panel monoclonal gammopathy of uncertain significance 23. Flanders A, Stetler-Stevenson M, Landgren O. 1. Blood. 2011;117(18):4691-4695. and smoldering multiple myeloma based on Minimal residual disease testing in multiple multiparameter flow cytometry analysis of bone myeloma by flow cytometry: major heterogeneity. 18. Richardson PG, Barlogie B, Berenson J, et al. marrow plasma cells. Blood. 2007;110:2586-2592. Blood. 2013;122(6):1088-1089. A phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med. 2003;348(26): 21. Dispenzieri A, Kyle RA, Katzmann JA, et al. 24. Landgren O, Gormley N, Turley D, et al. Flow 2609-2617. Immunoglobulin free light chain ratio is an cytometry detection of minimal residual disease in independent risk factor for progression of multiple myeloma: lessons learned at FDA-NCI 19. Faham M, Zheng J, Moorhead M, et al. smoldering (asymptomatic) multiple myeloma. Blood. roundtable symposium. Am J Hematol. 2014;89 Deep-sequencing approach for minimal residual 2008;111:785-789. (12):1159-1160. disease detection in acute lymphoblastic leukemia. Blood. 2012;120(26):5173-5180. 22. Mateos MV, Hernández MT, Giraldo P, et al. Lenalidomide plus dexamethasone for high-risk 20. Perez-Persona E, Vidriales MB, Mateo G, et al. smoldering multiple myeloma. N Engl J Med.2013; New criteria to identify http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png JAMA Oncology American Medical Association

Multiple Myeloma—Better Drugs Ask for More Stringent Evaluations

Sonneveld, Pieter
JAMA Oncology , Volume 1 (6) – Sep 1, 2015
Download PDF
2 pages

Loading next page...
 
/lp/american-medical-association/multiple-myeloma-better-drugs-ask-for-more-stringent-evaluations-XEYSKdmtLn
Publisher
American Medical Association
Copyright
Copyright 2015 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Restrictions Apply to Government Use.
ISSN
2374-2437
eISSN
2374-2445
DOI
10.1001/jamaoncol.2015.2009
pmid
26181637
Publisher site
See Article on Publisher Site

Abstract

Research Original Investigation Carfilzomib, Lenalidomide, and Dexamethasone With Lenalidomide International Myeloma Workshop Consensus Panel monoclonal gammopathy of uncertain significance 23. Flanders A, Stetler-Stevenson M, Landgren O. 1. Blood. 2011;117(18):4691-4695. and smoldering multiple myeloma based on Minimal residual disease testing in multiple multiparameter flow cytometry analysis of bone myeloma by flow cytometry: major heterogeneity. 18. Richardson PG, Barlogie B, Berenson J, et al. marrow plasma cells. Blood. 2007;110:2586-2592. Blood. 2013;122(6):1088-1089. A phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med. 2003;348(26): 21. Dispenzieri A, Kyle RA, Katzmann JA, et al. 24. Landgren O, Gormley N, Turley D, et al. Flow 2609-2617. Immunoglobulin free light chain ratio is an cytometry detection of minimal residual disease in independent risk factor for progression of multiple myeloma: lessons learned at FDA-NCI 19. Faham M, Zheng J, Moorhead M, et al. smoldering (asymptomatic) multiple myeloma. Blood. roundtable symposium. Am J Hematol. 2014;89 Deep-sequencing approach for minimal residual 2008;111:785-789. (12):1159-1160. disease detection in acute lymphoblastic leukemia. Blood. 2012;120(26):5173-5180. 22. Mateos MV, Hernández MT, Giraldo P, et al. Lenalidomide plus dexamethasone for high-risk 20. Perez-Persona E, Vidriales MB, Mateo G, et al. smoldering multiple myeloma. N Engl J Med.2013; New criteria to identify

Journal

JAMA Oncology – American Medical Association

Published: Sep 1, 2015

References

  • Treatment with carfilzomib-lenalidomide-dexamethasone with lenalidomide extension in patients with smoldering or newly diagnosed multiple myeloma [published online July 2, 2015].
    Korde, N; Roschewski, M; Zingone, A
  • Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction therapy before, and consolidation therapy after, double autologous stem-cell transplantation in newly diagnosed multiple myeloma: a randomised phase 3 study.
    Cavo, M; Tacchetti, P; Patriarca, F
  • Lenalidomide, bortezomib, and dexamethasone in patients with newly diagnosed multiple myeloma: encouraging efficacy in high risk groups with updated results of a phase I/II study.
    Richardson, P
  • Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma.
    Stewart, AK; Rajkumar, SV; Dimopoulos, MA
  • A phase 1/2 study of carfilzomib in combination with lenalidomide and low-dose dexamethasone as a frontline treatment for multiple myeloma.
    Jakubowiak, AJ; Dytfeld, D; Griffith, KA
  • Phase 2 study of carfilzomib, thalidomide, and dexamethasone as induction/consolidation therapy for newly diagnosed multiple myeloma.
    Sonneveld, P; Asselbergs, E; Zweegman, S
  • International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma.
    Rajkumar, SV; Dimopoulos, MA; Palumbo, A